诺和锐30和诺和灵30R治疗老年2型糖尿病的对比研究

Comparison of BIAsp30 and BHI30 in the treatment of elder patients with type 2 diabetes mellitus

目的比较诺和锐30和诺和灵30R每日2次皮下注射在治疗老年2型糖尿病(T2DM)患者的疗效和安全性。方法为期12周的随机、开放性比较研究。80例T2DM患者被随机分为诺和锐30治疗组和诺和灵30R治疗组,采用每日早、晚餐前两次皮下注射方案,观察两组患者5个时点血糖、糖化血红蛋白(HbA1C)、低血糖事件及其他不良事件的差异。结果诺和锐30治疗组三餐后血糖水平明显低于诺和灵30R治疗组(P<0.05);诺和锐30组低血糖发生次数低于诺和灵30R组,严重低血糖发生次数约为诺和灵30R组的45%;两组HbA1C、胰岛素用量及其他不良事件差异无统计学意义。结论对血糖控制不佳的老年糖尿病患者,尽早使用诺和锐30R,能使血糖控制更平稳,且低血糖发生率低。

OBJECTIVE To compare the efficacy and safety of biphasic insulin aspart 30（BIAsp30） and biphasic human insulin 30（BHI30） in elder patients with type 2 diabetes mellitus （T2 DM） who begin to use insulin.METHODS A 12 week open and random study was performed.All 80 elder patients with T2 DM were randomly divided into 2 groups. One group was treated by BIAsp30 and the other by BHI30. Both drugs were respectively injected subcutaneously to the patients. Blood glucose at 5 time points, glycosylated hemoglobin and hypoglycemia were observed. RESULTS The postprandial blood glucose was significantly lower in BIAsp30 group than in BHI30 one（P〈0.05）, and the frequency of hypoglycemia was lower in BIAsp30 group than in the other one. There was no difference between glycosylated hemoglobin and dosage of insulin.CONCLUSION In order to control early hyperglycemia for elder patients with T2DM, using BIAsp 30 could make blood glucose more steady, and the rate of hypoglycemia is lower.